Daiichi Sankyo Company, Limited DSNKY
17.80 USD -1.30 (-6.81%)
Nov 6, 2026, 3:52 PM EST
17.27 Day range 17.87
14.98 52-week range 24.77
- YTD
- -16.20%
- 1 year
- -19.60%
- Market cap
- 32.43B
- EPS (ttm)
- 0.97
- P/E ratio
- 18.35
- YTD return
- -16.20%
- 1-year return
- -19.60%
- Volume
- 9.09K
- Avg volume
- 147.90K
- Open
- 17.35
- Previous close
- 19.10
- Day's range
- 17.27 – 17.87
- 52-week range
- 14.98 – 24.77
- Earnings date
- Oct 30, 2026
15m -0.40 (-2.20%)
Next earnings
Oct 30, 2026
Expected Oct 30, 2026. Consensus EPS estimate 0.2362.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2026 | Sep 30, 2026 | 0.2362 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 0.2543 | 0.24 | -0.01 | -5.62% |
| May 11, 2026 | Mar 31, 2026 | 0.3317 | 0.1465 | -0.19 | -55.83% |
| Jan 29, 2026 | Dec 31, 2025 | 0.2504 | 0.3033 | +0.05 | +21.13% |
| Oct 31, 2025 | Sep 30, 2025 | 0.2986 | 0.1592 | -0.14 | -46.68% |
| Jul 31, 2025 | Jun 30, 2025 | 0.2337 | 0.3059 | +0.07 | +30.89% |
News
Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call Transcript 
Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1 
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership 
Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study 
Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial 
Daiichi Sankyo And AstraZeneca's Enhertu Shows Significant PFS Improvement As First-Line HER2 Mutant NSCLC Treatment In DESTINY-Lung04 Phase 3 Trial - Organon Signs Commercialization Agreement For Daiichi Sankyo's Nilemdo To Strengthen Cardiovascular Disease Portfolio In France And Nordic Countries
- Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
- Earnings Scheduled For July 31, 2020
Stocks That Hit 52-Week Highs On Thursday
Your note
Sign in to keep a note on DSNKY — it syncs with the Stock Master app.